Received the ACE Award for cutting-edge innovation from the American Orthopedic Society for Sports Medicine (AOSSM) for Tactoset Injectable Bone Substitute for hardware augmentation.
Cingal® successfully achieved its primary endpoint in its third Phase III clinical trial.